journal article
LitStream Collection
2006 Journal of Thoracic Oncology
ILK inhibitor does not enhance the toxicity of standard chemotherapy and may have a beneficial therapeutic effect in lung cancer.
2006 Journal of Thoracic Oncology
The present results suggest that NNAT has the potential to be used as a differential maker between LCNEC and SCLC.
2006 Journal of Thoracic Oncology
Modern radiotherapy is a reasonable option for patients to consider for stage I NSCLC and is recommended for medically inoperable patients rather than supportive care or observation.
2006 Journal of Thoracic Oncology
Single-fraction stereotactic RT is feasible for selected patients with lung tumors. For those with prior thoracic RT, 25 Gy may be too toxic. Higher dose was associated with improved local control. Longer follow-up is necessary to determine the treatment efficacy and toxicity.
2006 Journal of Thoracic Oncology
This regimen produced promising overall survival in patients with stage III NSCLC, but the vast majority of patients could not continue with the docetaxel consolidation because of toxicity.
2006 Journal of Thoracic Oncology
In addition to performance status and weight loss, patient-reported appetite loss should be assessed in stage III NSCLC patients before administrating TRT; such assessment is a valuable tool for selecting patients to normofractionated or lower-dose hypofractionated palliative TRT.
Showing 1 to 10 of 19 Articles